Clinical Trial

Eurofins Viracor's new assay delivers rapid insights into CAR T-cell performance, promising faster, more personalized decisions for cancer patients.

Tanabe Pharma Canada's 'Letters to ALS' offers a raw, intimate look into the fight against the disease, strengthening community bonds through shared stories.

Healthcare powerhouse Terri Cooper joins Morphic Medical's board, a strategic move to navigate clinical trials for its non-surgical RESET diabetes therapy.

A new lithium formula boosts brain delivery in a key trial, offering hope for safer, more effective treatments for Alzheimer's, bipolar disorder, and more.

A new RNA drug shows promise by reducing harmful belly fat while preserving muscle, but modest overall weight loss in early trials spooks investors.

Aerin Medical's milestone highlights a major shift toward minimally invasive, in-office treatments for chronic nasal issues, moving beyond traditional surgery.

A new FDA-cleared device uses water vapor to ablate prostate tissue, showing high efficacy in trials while minimizing life-altering side effects.

Riding high on record 2025 results and a new FDA approval, LivaNova faces intense scrutiny ahead of its May 6 earnings call. Can it sustain the momentum?

With $138M in total funding, Endogenex is advancing a novel device that aims to redefine type 2 diabetes treatment by healing the gut, not just managing symptoms.

Swedish biotech VERIGRAFT begins a pivotal trial for a personalized, lab-grown vein, offering hope for a true cure for millions with chronic venous insufficiency.

The scientist behind PARP inhibitors is backing a new approach. Dr. Alan Ashworth's appointment at Leapfrog Bio signals a major push in precision oncology.

With new financing from Avenue Capital, Turn Therapeutics bets big on its novel skin therapy, GX-03, to tackle multi-billion dollar dermatology markets.

A US-Japan biotech firm secures major funding to advance a first-in-class drug, offering new hope for millions with inherited blood disorders.

RA Capital's major investment extends Karyopharm's runway, but future funding is now directly tied to the outcome of its pivotal endometrial cancer trial.

A new Phase 2 trial is testing an inhaled version of a key IPF drug, aiming to reduce severe side effects and transform treatment for the fatal lung disease.

With over AUD$1M in sales from its first MDMA batch, Cortexa is validating Australia's pioneering move to legalize psychedelic-assisted therapy.

Sydnexis's eye drop trial shows high efficacy in children 3-12, positioning it as a potential first-of-its-kind FDA-approved drug for myopia.

With key trial enrollment complete, Pyxis Oncology refines its cancer drug MICVO for safety and prepares for pivotal data under a new, seasoned CEO.

Interna Therapeutics, Oxford, and the Gates Foundation team up on a novel intranasal siRNA spray to prevent COVID, tested in a human challenge trial.

With a promising non-opioid drug and new leadership known for major deals, Persica Pharmaceuticals is poised to revolutionize back pain treatment.